A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
Status:
Completed
Trial end date:
2021-07-23
Target enrollment:
Participant gender:
Summary
This study will assess the effect of food on the pharmacokinetics (PK) of pediatric
formulations of TRIUMEQ (dolutegravir [DTG] 5 milligrams [mg]/abacavir [ABC] 60 mg/lamivudine
[3TC] 30 mg) dispersible tablets and DOVATO (DTG 5 mg/3TC 30 mg) dispersible tablets in
healthy adult participants. Additionally, safety and tolerability of these formulations will
also be assessed. TRIUMEQ and DOVATO are registered trademarks of GlaxoSmithKline group of
companies.